PURPOSE: The aims of this study were to investigate the psychometric properties of the Norwegian version of the short health scale (SHS), and to study the impact of socio-demographic and clinical data. METHODS: A total of 140 patients without severe disease activity were included. The participants completed the SHS and three other well-validated HRQoL questionnaires short form 36, inflammatory bowel disease questionnaire and the rating form of inflammatory bowel disease patient concerns at the baseline. Sixty-three participants completed the SHS at a second visit after 6 months in order to calculate test-retest reliability and responsiveness. In addition, socio-demographic and clinical variables were obtained and entered into a linear regression analysis if they were found to be significantly associated with SHS outcome. RESULTS: Validity was confirmed by good correlation with other similar HRQoL constructs and the ability to discriminate between IBD symptom scores. The reliability was strong (Cronbach's α 0.85). The test-retest reliability in three out of four SHS items was weak, but the questionnaire demonstrated a good responsiveness. Current IBD symptoms were the most important predictor of SHS outcome. CONCLUSIONS: The Norwegian SHS demonstrated satisfactory psychometrical properties and is suitable for use in the follow-up of IBD patients.
PURPOSE: The aims of this study were to investigate the psychometric properties of the Norwegian version of the short health scale (SHS), and to study the impact of socio-demographic and clinical data. METHODS: A total of 140 patients without severe disease activity were included. The participants completed the SHS and three other well-validated HRQoL questionnaires short form 36, inflammatory bowel disease questionnaire and the rating form of inflammatory bowel diseasepatient concerns at the baseline. Sixty-three participants completed the SHS at a second visit after 6 months in order to calculate test-retest reliability and responsiveness. In addition, socio-demographic and clinical variables were obtained and entered into a linear regression analysis if they were found to be significantly associated with SHS outcome. RESULTS: Validity was confirmed by good correlation with other similar HRQoL constructs and the ability to discriminate between IBD symptom scores. The reliability was strong (Cronbach's α 0.85). The test-retest reliability in three out of four SHS items was weak, but the questionnaire demonstrated a good responsiveness. Current IBD symptoms were the most important predictor of SHS outcome. CONCLUSIONS: The Norwegian SHS demonstrated satisfactory psychometrical properties and is suitable for use in the follow-up of IBD patients.
Authors: Henrik Hjortswang; Gunnar Järnerot; Bengt Curman; Hanna Sandberg-Gertzén; Curt Tysk; Björn Blomberg; Sven Almer; Magnus Ström Journal: Scand J Gastroenterol Date: 2006-10 Impact factor: 2.423
Authors: T Bernklev; J Jahnsen; E Aadland; J Sauar; T Schulz; I Lygren; M Henriksen; N Stray; O Kjellevold; M Vatn; B Moum Journal: Scand J Gastroenterol Date: 2004-04 Impact factor: 2.423
Authors: Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey Journal: Qual Life Res Date: 2017-08-28 Impact factor: 4.147